It's tough when something like this happens with a private company. It's tough to dig up financial information.
I'm just going to dump some findings here...
Nov. 2004
PharmAthene, Inc., a biotechnology company developing a comprehensive array of countermeasures to bioterrorism, announced the closing of $50 Million in Series B Financing. The deal was led by MPM Capital and co-led by Bear Stearns Health Innoventures. HealthCare Ventures, the sole Series A Round investor, also participated. This Series B Financing will enable PharmAthene to continue development of ToxBloxTM, a potent inhibitor of anthrax toxin being developed as a treatment for symptomatic patients, and to pursue other in-licensing and acquisition opportunities.
April 2005
Nexia Biotechnologies Inc. Completes Sale Of Protexia Operations, Assets To PharmAthene, Inc.; PharmAthene Closes $11.2 Series C
MONTREAL (CP) - Nexia Biotechnologies Inc. has completed the sale of its operations and assets related to its Protexia business to PharmAthene, Inc. for $11.2 million US in cash plus securities, the company announced Monday. Protexia is a drug designed to protect the military from biological weapons. In addition to the cash, Nexia also gets approximately 7.5 million series C convertible preferred shares of PharmAthene, 2.3 million warrants to acquire series C preferreds and 1.3 million warrants to acquire PharmAthene common shares. |
